Child Neurology: Aicardi-Goutières Syndrome Presenting as Recurrent Ischemic Stroke.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 35803721.
- Also identified by DOI 10.1212/WNL.0000000000200952 and PMC identifier 9502735.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aicardi-Goutières syndrome (AGS) is a rare, single-gene disorder, characterized by neurologic and skin involvement with an increased level of interferon-α (IFN-α) in the CSF. We describe the case of a young patient presenting with recurrent ischemic stroke. Evaluation revealed the presence of chilblains, white matter abnormalities, cerebral atrophy, and raised IFN-α in the CSF. Compound heterozygous variants of <i>TREX1</i> were detected, confirming a diagnosis of AGS. After excluding other causes, we attributed the stroke to AGS. Tofacitinib, a Janus kinase inhibitor, was administered to our patient in addition to antiplatelet drugs. There was no recurrence of stroke during 3-month follow-up. This is a rare case of recurrent stroke in <i>TREX1</i>-mutated AGS. Small vessel involvement has been previously demonstrated to play a significant role in the pathogenesis of AGS. This microvascular mechanism might explain the occurrence of ischemic stroke in our patient. For young patients with stroke and multiple system involvement, genetic disorders including AGS should be considered.
Medical subject headings
- Autoimmune Diseases of the Nervous System
- Ischemic Stroke
- Janus Kinase Inhibitors
- Nervous System Malformations
- Neurology